Pfizer is recalling more than four million packages of the NurseTech ODT prescription migraine drug because of a risk of poisoning children because of a failure to meet child-resistant packaging safety requirements.
The U.S. Consumer Product Safety Commission said Thursday that the company is recalling approximately 4.2 million units of Narstech ODT (rimagepent) 75mg orally disintegrating tablets, which are sold in eight-dose packs on blister cards. The commission said that anyone affected would be able to obtain a free child-resistant pouch to store the product.
The Safety Commission stated that prescription drugs are required to be in child-resistant packaging, as mandated in the Poison Prevention Packaging Act.
“The packaging of the products is not child-resistant, posing a risk of toxicity if the contents are swallowed by young children,” it warned.
Consumers were told to “immediately secure the recalled product out of the sight and reach of children and contact Pfizer for a free child-resistant pouch to store the product.”
The commission said that once consumers have secured the medicine in the pouch, they can continue to use it as directed.
The safety commission said that till Thursday, no incident had been registered in relation to the issue.
Nartec ODT shares news of the recall Twitter and posted a statement on its website saying that Pfizer “recently determined that Nartec ODT packaging does not meet child-resistant packaging requirements for oral prescription drugs if the contents are swallowed by young children.” could potentially pose a risk of harm.”
While patients will still be able to keep the child-resistant pouch to store the product after receiving it, the Nurtec ODT notes that the Safety Commission “will refer to any repair, replacement, refund, or notice/warning describing the ‘recall’.” ‘ uses the word. program.”
Nartec ODT said Pfizer was working to create new packaging for the migraine drug to comply with child-resistant packaging requirements. Meanwhile, it said pharmacists will keep blister packages on vials with child-resistant lids when filling patient prescriptions.
The safety commission said the drug was distributed in pharmacies nationwide from December 2021 to March 2023 as a prescribed drug.
Pfizer did not immediately respond to an overnight request for comment.